This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY
by Zacks Equity Research
Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.
Biogen (BIIB) Stock Down Despite FDA Nod to Alzheimer's Drug
by Zacks Equity Research
Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease.
Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's
by Zacks Equity Research
Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage.
Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More
by Zacks Equity Research
Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.
Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement
by Zacks Equity Research
An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9.
Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod
by Zacks Equity Research
Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
by Zacks Equity Research
Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector.
Mastering the Double-Bottom Pattern (Unveiling 3 Intriguing Setups in Today's Market)
by Andrew Rocco
A double-bottom base is a chart pattern commonly used in technical analysis to identify a solid reward-to-risk zone in a stock. Stock Strategist Andrew Rocco walks you through the pattern and unveils 3 juicy setups.
Novo Nordisk and Golden Entertainment have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article.
Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122
by Zacks Equity Research
Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's
Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study
by Zacks Equity Research
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
Cassava (SAVA) Up on Progress With Alzheimers Disease Study
by Zacks Equity Research
Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.
Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen Inc. (BIIB) Up 4.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far
by Zacks Equity Research
Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.
Should iShares Morningstar Mid-Cap Value ETF (IMCV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCV
Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
The Zacks Analyst Blog Highlights Exxon Mobil, Costco Wholesale, Activision Blizzard, Biogen and Arista Networks
by Zacks Equity Research
Exxon Mobil, Costco Wholesale, Activision Blizzard, Biogen and Arista Networks are part of the Zacks top Analyst Blog.
Top Analyst Reports for Exxon Mobil, Costco & Activision Blizzard
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Costco Wholesale Corporation (COST), and Activision Blizzard, Inc. (ATVI).
Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match
by Zacks Equity Research
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.
The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio
by Zacks Equity Research
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
by Ekta Bagri
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs
by Zacks Equity Research
Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.
Biogen Inc. (BIIB) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Biogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 4.62% and 5%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?